

Articles published by Sheba researchers on the subject of cancer

Year 2007

(IF - Impact Factor top 500 scientific journals)

1. Abraham M, Biyder K, Begin M, Wald H, Weiss ID, Galun E, Nagler A, Peled A. **Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003.** Stem Cells. 2007 Sep;25(9):2158-66 (IF 7.924)
2. Amariglio N, Rechavi G. **A-to-I RNA editing: A new regulatory mechanism of global gene expression.** Blood Cells Mol Dis. 2007 Sep-Oct;39(2):151-5 (IF 2.678)
3. Amariglio N, Jacob-Hirsch J, Shimoni A, Leiba M, Rechavi G, Nagler A. **Changes in gene expression pattern following granulocyte colony-stimulating factor administration to normal stem cell sibling donors.** Acta Haematol. 2007;117(2):68-73 (IF 1.564)
4. Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F, Tarcic G, Siwak D, Lahad J, Jacob-Hirsch J, Amariglio N, Vaisman N, Segal E, Rechavi G, Alon U, Mills GB, Domany E, Yarden Y. **A module of negative feedback regulators defines growth factor signaling.** Nat Genet. 2007 Apr;39(4):503-12 (IF 25.797)
5. Amit M, Sela N, Keren H, Melamed Z, Muler I, Shomron N, Izraeli S, Ast G. **Biased exonization of transposed elements in duplicated genes: A lesson from the TIF-IA gene.** BMC Mol Biol. 2007 Nov 29;8(1):109 (IF 3.500)
6. Amsalem Y, Mardor Y, Feinberg MS, Landa N, Miller L, Daniels D, Ocherashvili A, Holbova R, Yosef O, Barbash IM, Leor J. **Iron-oxide labeling and outcome of transplanted mesenchymal stem cells in the infarcted myocardium.** Circulation. 2007 Sep 11;116(11):I38-45 (IF 10.940)
7. Arien-Zakay H, Nagler A, Galski H, Lazarovici P. **Neuronal conditioning medium and nerve growth factor induce neuronal differentiation of collagen-adherent progenitors derived from human umbilical cord blood.** J Mol Neurosci. 2007;32(3):179-91 (IF 2.965)
8. Ashur-Fabian O, Adamsky K, Trakhtenbrot L, Cohen Y, Raanani P, Hardan I, Nagler A, Rechavi G, Amariglio N. **Apaf1 in Chronic Myelogenous Leukemia (CML) Progression: Reduced Apaf1 Expression is Correlated with a H179R p53 Mutation During Clinical Blast Crisis.** Cell Cycle. 2007 Mar;6(5) 589-94 (IF 3.214)
9. Ashur-Fabian O, Amariglio N, Cohen Y, Nagler A, Rechavi G, Salomon O. **The disappearance of two alleles of JAK2 V617F from peripheral blood of a polycythaemia vera patient correlates with transformation into myelofibrosis.** Br J Haematol. 2007 Sep; 138(6):822-3. (IF 4.498)
10. Atwal GS, Bond GL, Metsuyanin S, Papa M, Friedman E, Distelman-Menachem T, Ben Asher E, Lancet D, Ross DA, Sninsky J, White TJ, Levine AJ, Yarden R. **Haplotype structure and selection of the MDM2 oncogene in humans.** Proc Natl Acad Sci U S A. 2007 Mar 13; 104(11):4524-9. (IF 10.231)

11. Bader D, Datz H, Bartal G, Juster AA, Marks K, Smolkin T, Zangen S, Kugelman A, Hoffmann C, Shani G, Ben-Shlomo A, Margalio M, Sadetzki S. **Unintentional exposure of neonates to conventional radiography in the Neonatal Intensive Care Units.** J Perinatol. 2007 Sep;27(9):579-85
12. Bakhanashvili M, Gedelovich R, Grinberg S, Rahav G. **Exonucleolytic degradation of RNA by p53 protein in cytoplasm.** J Mol Med. 2007 Aug 15 [Epub ahead of print] (IF 5.157)
13. Baser S, Onn A, Lin E, Morice RC, Duvic M. **Pulmonary manifestations in patients with cutaneous T-cell lymphomas.** Cancer. 2007 Apr 15; 109(8):1550-5. (IF 4.582)
14. Barsheshet A, Hod H, Shechter M, Sharabani-Yosef O, Rosenthal E, Barbash IM, Matetzky S, Tal R, Bentancur AG, Sela BA, Nagler A, Leor J. **The Effects of External Counter Pulsation Therapy on Circulating Endothelial Progenitor Cells in Patients with Angina Pectoris.** Cardiology. 2007 Dec 4; 110(3):160-166 (IF 1.795)
15. Betts DR, Stanchesu R, Niggli FK, Cohen N, Rechavi G, Amariglio N, Trakhtenbrot L. **SKY reveals a high frequency of unbalanced translocations involving chromosome 6 in t(12;21)-positive acute lymphoblastic leukemia.** Leuk Res. 2008 Jan; 32 (1): 39-43 (IF 2.483)
16. Binderman I, Bahar H, Jacob-Hirsch J, Zeligson S, Amariglio N, Rechavi G, Shoham S, Yaffe A. **P2X4 is up-regulated in gingival fibroblasts after periodontal surgery.** J Dent Res. 2007 Feb; 86(2):181-5. (IF 3.192)
17. Blum R, Elkon R, Yaari S, Zundelovich A, Jacob-Hirsch J, Rechavi G, Shamir R, Kloog Y. **Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).** Cancer Res. 2007 Apr 1; 67(7):3320-8. (IF 7.656)
18. Cardis E, Richardson L, Deltour I, Armstrong B, Feychting M, Johansen C, Kilkenney M, McKinney P, Modan B, Sadetzki S, et al. **The INTERPHONE study: design, epidemiological methods, and description of the study population.** Eur J Epidemiol. 2007 Jul 18; [Epub ahead of print] (IF 1.605)
19. Cario G, Izraeli S, Teichert A, Rhein P, Skokowa J, Moricke A, Zimmermann M, Schrauder A, Karawajew L, Ludwig WD, Welte K, Schunemann HJ, Schlegelberger B, Schrappe M, Stanulla M. **High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS.** J Clin Oncol. 2007 Oct 20;25(30):4813-20. (IF 13.598)
20. Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, Kovacs K, Wawrowsky K, Melmed S. **Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth.** Cancer Res. 2007 Nov 1; 67(21): 10564-72. (IF 7.656)
21. Dehan E, Ben-Dor A, Liao W, Lipson D, Frimer H, Riesenstein S, Simansky D, Krupsky M, Yaron P, Friedman E, Rechavi G, Perlman M, Aviram-Goldring A, Izraeli S, Bittner M, Yakhini Z, Kaminski N. **Chromosomal aberrations and gene expression profiles in non-small cell lung cancer.** Lung Cancer. 2007 May;56(2):175-84 (IF 3.172)
22. Dekel B, Metsuyanin S, Garcia AM, Quintero C, Sanchez MJ, Izraeli S. **Organ-injury-induced reactivation of hemangioblastic precursor cells.** Leukemia. 2007 Sep 27; [Epub ahead of print] (IF 6.146)
23. Dotan ZA, Ramon J. **Staging of prostate cancer.** Recent Results. Cancer Res. 2007;175: 109-30. Review. (IF 7.656)

24. Elizur SE, Beiner ME, Korach J, Weiser A, Ben-Baruch G, Dor J. **Outcome of in vitro fertilization treatment in infertile women conservatively treated for endometrial adenocarcinoma.** Fertil Steril. 2007 Apr 3; [Epub ahead of print] (IF 3.277)
25. Erez A, Castiel A, Trakhtenbrot L, Perelman M, Rosenthal E, Goldstein I, Stettner N, Harmelin A, Eldar-Finkelman H, Campaner S, Kirsch I, Izraeli S. **The SIL gene is essential for mitotic entry and survival of cancer cells.** Cancer Res. 2007 May 1;67(9):4022-7. Erratum in: Cancer Res. 2007 Jun 15;67(12):5998. (IF 7.656)
26. Finke J, Nagler A. **Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning - is there still an upper age limit? A focus on myeloid neoplasia.** Leukemia. 2007 Jul;21(7):1357-62 (IF 6.146)
27. Fisher T, Galanti G, Lavie G, Jacob-Hirsch J, Kventsel I, Zeligson S, Winkler R, Simon AJ, Amariglio N, Rechavi G, Toren A. **Mechanisms Operative in the Antitumor Activity of Temozolomide in Glioblastoma Multiforme.** Cancer J. 2007 Sep-Oct ;13(5): 335-44 (IF 2.0280)
28. Flint-Richter P, Sadetzki S. **Genetic predisposition for the development of radiation associated meningioma: an epidemiological study.** Lancet Oncology 2007; 8: 403-410. (IF 9.608)
29. Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalova K, Stark B, Harrison CJ, Teigler-Schlegel A, Johansson B. **Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome - an iBFM-SG study.** Blood. 2007 Oct 30; [Epub ahead of print] (IF 10.370)
30. Gal H, Makovitzki A, Amariglio N, Rechavi G, Ram Z, Givol D. **A rapid assay for drug sensitivity of glioblastoma stem cells.** Biochem Biophys Res Commun. 2007 Jul 6;358(3):908-13 (IF 2.855)
31. Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A, Nagler A, Tavor S, Ein-Dor L, Lapidot T, Domany E, Rechavi G, Givol D. **Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells.** Leukemia. 2006 Dec;20(12):2147-54 (IF 6.146)
32. Galanti G, Fisher T, Kventsel I, Shoham J, Gallily R, Mechoulam R, Lavie G, Amariglio N, Rechavi G, Toren A. **Delta9- Tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells.** Acta Oncol. 2007 Oct 12;:1-9 [Epub ahead of print] (IF 1.856)
33. Galore G, Azizi E, Scope A, Pavlotsky F, Yakobson E, Friedman E. **The Y152X MC1R gene mutation: occurrence in ethnically diverse Jewish malignant melanoma patients.** Melanoma Res. 2007 Apr;17(2):105-8 (IF 1.704)
34. Gardenghi S, Marongiu MF, Ramos P, Guy E, Breda L, Chadburn A, Liu Y, Amariglio N, Rechavi G, Rachmilewitz EA, Breuer W, Cabantchik ZI, Wrighting DM, Andrews NC, de Sousa M, Giardina PJ, Grady RW, Rivella S. **Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin.** Blood. 2007 Jun 1; 109(11):5027-35. (IF 10.370)
35. Gisselbrecht C, Bethge W, Duarte RF, Gianni AM, Glass B, Haioun C, Martinelli G, Nagler A, Pettengell R, Sureda A, Tilly H, Wilson K. **Current**

- status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma.** Bone Marrow Transplant. 2007 Dec ; 40(11): 1007-17 (IF 2.621)
36. Gnainsky Y, Kushnirsky Z, Bilu G, Hagai Y, Genina O, Volpin H, Bruck R, Spira G, Nagler A, Kawada N, Yoshizato K, Reinhardt DP, Libermann TA, Pines M. **Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling.** Cell Tissue Res. 2007 Apr;328(1):153-66. (IF 2.580)
 37. Goldstein G, Toren A, Nagler A. **Transplantation and other uses of human umbilical cord blood and stem cells.** Curr Pharm Des. 2007;13(13):1363-73. (IF 5.270)
 38. Goldstein I, Ben-Horin S, Koltakov A, Chermoshnuk H, Polevoy V, Berkun Y, Amariglio N, Bank I. **a1b1 Integrin+ and Regulatory Foxp3+ T cells constitute two Functionally Distinct Human CD4+ T cell Subsets Oppositely Modulated by TNFa Blockade.** J Immunol 2007; 178:201-10. (IF 6.387)
 39. Gratzinger D, Zhao S, Tibshirani RJ, Hsi ED, Hans CP, Pohlman B, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE Jr, Lossos IS, Natkunam Y. **Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy.** Lab Invest. 2007 Nov 12; [Epub ahead of print] (IF 4.453)
 40. Gupta S, Jain A, Warneke CL, Gupta A, Shannon VR, Morice RC, Onn A, Jimenez CA, Bashoura L, Giralt SA, Dickey BF, Eapen GA. **Outcome of alveolar hemorrhage in hematopoietic stem cell transplant recipients.** Bone Marrow Transplant 2007; 40(1): 71-8. (IF 2.621)
 41. Haberman Y, Amariglio N, Rechavi G, Eisenberg E. **Trinucleotide repeats are prevalent among cancer-related genes.** Trends Genet. 2008 Jan; 24(1):14-8. (IF 9.950)
 42. Herbst RS, Heymach JV, O'Reilly MS, Onn A and Ryan AJ. **Vandetanib (ZD6474) – an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumour growth and angiogenesis.** Expert Opin Investig Drugs 2007; 16(2): 239-249. (IF 3.174)
 43. Hertzberg L, Izraeli S, Domany E. **STOP: searching for Transcription Factor motifs using gene expression.** Bioinformatics. 2007 Jul 15; 23(14): 1737-43 (IF 4.894)
 44. Hirshberg A, Yarom N, Amariglio N, Yahalom R, Adam I, Stanchesu R, Ben-Dov I, Taicher S, Rechavi G, Trakhtenbrot L. **Detection of non-diploid cells in premalignant and malignant oral lesions using combined morphological and FISH analysis - a new method for early detection of suspicious oral lesions.** Cancer Lett. 2007 Aug 18;253(2):282-90. (IF 3.277)
 45. Hochberg M, Zeligson S, Amariglio N, Rechavi G, Ingber A, Enk CD. **Genomic-scale analysis of psoriatic skin reveals differentially expressed insulin-like growth factor-binding protein-7 after phototherapy.** Br J Dermatol. 2007 Feb;156(2):289-300. (IF 3.334)
 46. Ilan Y, Ohana M, Pappo O, Margalit M, Lalazar G, Engelhardt D, Rabbani E, Nagler A. **Alleviation of Acute and Chronic Graft-Versus-Host Disease in a Murine Model Is Associated with Glucocerebroside-Enhanced Natural Killer T Lymphocyte Plasticity.** Transplantation. 2007 Feb 27;83(4):458-467. (IF 3.879)

47. Itasaka S, Komaki R, Herbst RS, Shibuya K, Shintani T, Hunter NR, Onn A, Bucana CD, Milas L, Ang KK, O'Reilly MS. **Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice.** *Int J Radiat Oncol Biol Phys* 2007; 67(3): 870-8. (IF 4.463)
48. Izraeli S, Rainis L, Hertzberg L, Smootha G, Birger Y. **Trisomy of chromosome 21 in leukemogenesis.** *Blood Cells Mol Dis.* 2007 Sep-Oct;39(2):156-9 (IF 2.678)
49. Kaplinsky C, Trakhtenbrot L, Izraeli S. **Could rhG-CSF induction of tetraploidy contribute to leukemogenesis in healthy donors?** *Br J Haematol.* 2007 Aug;138(4):558 (IF 4.498)
50. Katz M, Amit I, Citri A, Shay T, Carvalho S, Lavi S, Milanezi F, Lyass L, Amariglio N, Jacob-Hirsch J, Ben-Chetrit N, Tarcic G, Lindzen M, Avraham R, Liao YC, Trusk P, Lyass A, Rechavi G, Spector NL, Lo SH, Schmitt F, Bacus SS, Yarden Y. **A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration.** *Nat Cell Biol.* 2007 Aug; 9(8):961-9 (IF 18.485)
51. Katzenellenbogen M, Mizrahi L, Pappo O, Klopstock N, Olam D, Jacob-Hirsch J, Amariglio N, Rechavi G, Domany E, Galun E, Goldenberg D. **Molecular mechanisms of liver carcinogenesis in the mdx2-knockout mice.** *Mol Cancer Res.* 2007 Nov; 5(11):1159-70 (IF 4.759)
52. Kochupurakkal BS, Sarig R, Fuchs O, Piestun D, Rechavi G, Givol D. **Nanog inhibits the switch of myogenic cells towards the osteogenic lineage.** *Biochem Biophys Res Commun.* 2008 Jan 25;365(4):846-50 (IF 2.855)
53. Koren-Michowitz M, Hardan I, Berghoff J, Yshoev G, Amariglio N, Rechavi G, Nagler A, Trakhtenbrot L. **Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: A combined morphology and I-FISH analysis.** *Cancer Lett.* 2007 Oct 8;255(2):307-14 (IF 3.277)
54. Koren-Michowitz M, Shimoni A, Vivante A, Trakhtenbrot L, Rechavi G, Amariglio N, Loewenthal R, Nagler A, Cohen Y. **A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD).** *Leuk Res.* 2007 Aug 13; [Epub ahead of print] (IF 2.483)
55. Kundel Y, Yellin A, Popovtzer A, Pfeffer R, Symon Z, Simansky DA, Oberman B, Sadezki S, Brenner B, Catane R, Levitt ML. **Adjuvant radiotherapy for thymic epithelial tumor: treatment results and prognostic factors.** *Am J Clin Oncol.* 2007 Aug; 30(4):389-94. (IF 1.224)
56. Kundel Y, Brenner B, Symon Z, Oberman B, Sadezki S, Koller M, Catane R, Pfeffer R. **A phase II study of oral UFT and leucovorin concurrently with pelvic irradiation as neoadjuvant chemoradiation for rectal cancer.** *Anticancer Res.* 2007 Jul-Aug; 27(4C):2877-80. (IF 1.479)
57. Laitman Y, Kaufman B, Lahad EL, Papa MZ, Friedman E. **Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.** *Isr Med Assoc J.* 2007 Nov; 9(11):791-6. (IF 0.510)
58. Lande-Diner L, Zhang J, Ben-Porath I, Amariglio N, Keshet I, Hecht M, Azuara V, Fisher AG, Rechavi G, Cedar H. **Role of DNA methylation in**

- stable gene repression.** J Biol Chem. 2007 Apr 20;282(16):12194-200 (IF 5.854)
59. Levy-Lahad E, Friedman E. **Cancer risks among BRCA1 and BRCA2 mutation carriers.** Br J Cancer. 2007 Jan 15;96(1):11-5. Review. (IF 4.459)
 60. Malmer B, Adatto P, Armstrong G, Barnholtz-Sloan J, Bernstein JL, Claus E, Davis F, Houlston R, Il'yasova D, Jenkins R, Johansen C, Lai R, Lau C, McCarthy B, Nielsen H, Olson SH, Sadetzki S, Shete S, Wiklund F, Wrensch M, Yang P, Bondy M. **GLIOGENE an International Consortium to Understand Familial Glioma.** Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1730-4. (IF 4.289)
 61. Machtinger R, Inbar Y, Ben-Baruch G, Korach J, Rabinovici J. **MRgFUS for pain relief as palliative treatment in recurrent cervical carcinoma: A case report.** Gynecol Oncol. 2007 Oct 26; [Epub ahead of print] (IF 2.319)
 62. Maor S, Papa MZ, Yarden RI, Friedman E, Lerenthal Y, Lee SW, Mayer D, Werner H. **Insulin-like Growth Factor-I Controls BRCA1 Gene Expression through Activation of Transcription Factor Sp1.** Horm Metab Res. 2007 Mar;39(3):179-85 (IF 2.049)
 63. Maor S, Yosepovich A, Papa MZ, Yarden RI, Mayer D, Friedman E, Werner H. **Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations.** Cancer Lett. 2007 Nov 18; 257(2): 236-43 (IF 3.277)
 64. Meirow D, Baum M, Yaron R, Levron J, Hardan I, Schiff E, Nagler A, Yehuda DB, Raanani H, Hourvitz A, Dor J. **Ovarian tissue cryopreservation in hematologic malignancy: Ten years' experience.** Leuk Lymphoma. 2007 Aug; 48(8):1569-76. (IF 1.559)
 65. Meirow D, Dor J, Kaufman B, Shrim A, Rabinovici J, Schiff E, Raanani H, Levron J, Fridman E. **Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury.** Hum Reprod. 2007 Jun; 22(6):1626-33. (IF 3.769)
 66. Mizrahi S, Markel G, Porgador A, Bushkin Y, Mandelboim O. **CD100 on NK cells enhance IFNgamma secretion and killing of target cells expressing CD72.** PLoS ONE. 2007 Sep 5; 2(9):e818.
 67. Nachmias B, Mizrahi S, Elmalech M, Lazar I, Ashhab Y, Gazit R, Markel G, Ben-Yehuda D, Mandelboim O. **Manipulation of NK cytotoxicity by the IAP family member Livin.** Eur J Immunol. 2007 Dec 3; 37(12): 3467-76 (IF 4.772)
 68. Nadu A, Mor Y, Laufer M, Winkler H, Kleinmann N, Kitrey N, Ramon J. **Laparoscopic Partial Nephrectomy: Single Center Experience With 140 Patients-Evolution of the Surgical Technique and its Impact on Patient Outcomes.** J Urol. 2007 Aug;178(2):435-9; discussion 438-9 (IF 3.956)
 69. Nagler A, Ohana M, Leiba M, Levdansky L, Gorodetsky R. **Effect of Halofuginone, a Collagen alpha1(I) Inhibitor, on Wound Healing in Normal and Irradiated Skin: Implication for Hematopoietic Stem Cell Transplantation.** Acta Haematol. 2007 Jul 4; 118(2):77-83 (IF 1.229)
 70. Nazarian Y, Talmi YP, Wolf M, Horowitz Z, Bedrin L, Pfeffer R, Kronenberg J. **Recurrent pleomorphic adenomas of the parotid gland--treatment and outcome.** Harefuah. 2007 Feb;146(2):82-4, 168. [Article in Hebrew]
 71. Orłowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ,

- Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL. **Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.** J Clin Oncol. 2007 Sep 1;25(25):3892-901. (IF 13.598)
72. Ostrovsky O, Korostishevsky M, Levite I, Leiba M, Galski H, Vlodavsky I, Nagler A. **Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies.** Leukemia. 2007 Nov; 21(11): 2296-303 (IF 6.612)
 73. Onn A, Herbst RS. **Angiogenesis and lung cancer: implications for prognosis and treatment.** Lancet Oncol. 2007 Jun; 8(6):460-1. (IF 10.119)
 74. Oved K, Ziv O, Jacob-Hirsch J, Noy R, Novak H, Makler O, Galit D, Keren S, Segal D, Gefen-Dor C, Amariglio N, Rechavi G, Reiter Y. **A Novel Postpriming Regulatory Check Point of Effector/Memory T Cells Dictated through Antigen Density Threshold-Dependent Anergy.** J Immunol. 2007 Feb 15; 178(4):2307-17. (IF 6.387)
 75. Palomba G, Cossu A, Friedman E, Budroni M, Farris A, Contu A, Pisano M, Baldinu P, Sini MC, Tanda F, Palmieri G. **Origin and distribution of the BRCA2-8765delAG mutation in breast cancer.** BMC Cancer. 2007 Jul 19; 7:132. (IF 2.359)
 76. Pasvolsky R, Feigelson SW, Kilic SS, Simon AJ, Tal-Lapidot G, Grabovsky V, Crittenden JR, Amariglio N, Safran M, Graybiel AM, Rechavi G, Ben-Dor S, Etzioni A, Alon R. **A LAD-III syndrome is associated with defective expression of the Rap-1 activator CalDAG-GEFI in lymphocytes, neutrophils, and platelets.** J Exp Med. 2007 Jul 9; 204(7): 1571-82 (IF 14.484)
 77. Paz N, Levanon EY, Amariglio N, Heimberger AB, Ram Z, Constantini S, Barbash ZS, Adamsky K, Safran M, Hirschberg A, Krupsky M, Ben-Dov I, Cazacu S, Mikkelsen T, Brodie C, Eisenberg E, Rechavi G. **Altered adenosine-to-inosine RNA editing in human cancer.** Genome Res. 2007 Nov; 17(11): 1586-95 (IF 10.256)
 78. Pinthus JH, Pacik D, Ramon J. **Diagnosis of prostate cancer.** Recent Results. Cancer Res. 2007; 175:83-99. Review. (IF 7.656)
 79. Raccach E, Merimsky O, Kuten A, Apter S, Catane R. **Imatinib mesylate (glivec) as a treatment for gastrointestinal stromal tumor (GIST)--long term follow-up.** Harefuah. 2007 May;146(5):329-34, 408. Hebrew.
 80. Ramon J. **Nonlocalized renal cell carcinoma progresses rapidly.** Eur Urol. 2007 Jul;52(1):168-9. (IF 4.850)
 81. Rechavi O, Goldstein I, Vernitsky H, Rotblat B, Kloog Y. **Intercellular transfer of oncogenic h-ras at the immunological synapse.** PLoS ONE. 2007 Nov 21; 2(11): e1204.
 82. Rubinek T, Chesnokova V, Wolf I, Wawrowsky K, Vlotides G, Melmed S. **Discordant proliferation and differentiation in pituitary tumor-transforming gene-null bone marrow stem cells.** Am J Physiol Cell Physiol. 2007 Sep; 293(3): C1082-92. (IF 4.334)
 83. Sadetzki S, Chetrit A, Jarus-Hakak A, Cardis E, Deutch Y, Duvdevani S, Zultan A, Novikov I, Freedman L, Wolf M. **Cellular Phone Use and Risk of Benign and Malignant Parotid Gland Tumors A Nationwide Case-Control Study.** Am J Epidemiol. 2007 Dec 6; [Epub ahead of print] (IF 5.241)

84. Sadetzki S. **Excess lifetime cancer mortality risk attributed to radiation exposure from pediatric computed tomography scan.** Isr Med Assoc J. 2007 Aug; 9(8):607-9 (IF 0.510)
85. Schmid C, Labopin M, Nagler A, Bornhauser M, Finke J, Fassas A, Volin L, Gurman G, Maertens J, Bordigoni P, Holler E, Ehninger G, Polge E, Gorin NC, Kolb HJ, Rocha V. **Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party.** J Clin Oncol. 2007 Nov 1; 25(31): 4938-45 (IF 13.598)
86. Schmitz N, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E, Russell N, Apperley J, Szerm J, Bradstock K, Buzyn A, Schlegelberger B, Matcham J, Gratwohl A. **Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.** Haematologica. 2005 May; 90(5):643-8. (IF 5.032)
87. Shaklai S, Amariglio N, Rechavi G, Simon AJ. **Gene silencing at the nuclear periphery.** FEBS J. 2007 Mar; 274(6):1383-92. Review. (IF 3.033)
88. Shapira S, Barkan B, Friedman E, Kloog Y, Stein R. **The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways.** Cell Death Differ. 2007 May; 14(5):895-906. (IF 7.785)
89. Sheffer Y, Leon O, Pinthus JH, Nagler A, Mor Y, Genin O, Iluz M, Kawada N, Yoshizato K, Pines M. **Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect.** Mol Cancer Ther. 2007 Feb; 6(2):570-7 (IF 5.171)
90. Shimoni A, Nagler A. **Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma.** Leuk Lymphoma. 2007 Sep 19;:1-11 [Epub ahead of print] (IF 1.559)
91. Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. **Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.** Exp Hematol. 2007 Apr; 35(4):534-40. (IF 4.019)
92. Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Rand A, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. **Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma.** Bone Marrow Transplant. 2007 Nov 19; [Epub ahead of print] (IF 2.621)
93. Shimoni A, Hardan I, Shem-Tov N, Rand A, Herscovici C, Yerushalmi R, Nagler A. **Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.** Leukemia. 2007 Oct; 21(10): 2109-16 (IF 2.483)
94. Shimoni A, Hardan I, Shem-Tov N, Rand A, Yerushalmi R, Nagler A. **Fludarabine and treosulfan: A novel modified myeloablative regimen for**

- allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes.** *Leuk Lymphoma*. 2007 Dec; 48(12):2352-9. (IF 1.559)
95. Somech R, Nili Gal-Yam E, Shaklai S, Geller O, Amariglio N, Rechavi G, Simon AJ. **Enhanced expression of the nuclear envelope LAP2 transcriptional repressors in normal and malignant activated lymphocytes.** *Ann Hematol*. 2007 Jun; 86(6):393-401 (IF 2.193)
 96. Spiegel A, Shvitiel S, Kalinkovich A, Ludin A, Netzer N, Goichberg P, Azaria Y, Resnick I, Hardan I, Ben-Hur H, Nagler A, Rubinstein M, Lapidot T. **Catecholaminergic neurotransmitters regulate migration and repopulation of immature human CD34(+) cells through Wnt signaling.** *Nat Immunol*. 2007 Oct; 8(10): 1123-31 (IF 27.596)
 97. Stern-Ginossar N, Nedvetzki S, Markel G, Gazit R, Betser-Cohen G, Achdout H, Aker M, Blumberg RS, Davis DM, Appelmeik B, Mandelboim O. **Intercellular transfer of carcinoembryonic antigen from tumor cells to NK cells.** *J Immunol*. 2007 Oct 1; 179(7):4424-34. (IF 6.293)
 98. Vivante A, Amariglio N, Koren-Michowitz M, Ashur-Fabian O, Nagler A, Rechavi G, Cohen Y. **High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations.** *Leukemia*. 2007 Jun; 21(6):1318-21 (IF 6.612)
 99. Weizer-Stern O, Adamsky K, Margalit O, Ashur-Fabian O, Givol D, Amariglio N, Rechavi G. **Hepcidin, a key regulator of iron metabolism, is transcriptionally activated by p53.** *Br J Haematol*. 2007 Jul; 138(2):253-62. (IF 4.08)
 100. Wolf I, Ben-Baruch N, Shapira-Frommer R, Rizel S, Goldberg H, Yaal-Hahoshen N, Klein B, Geffen DB, Kaufman B. **Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study.** *Cancer*. 2007 Dec 12; [Epub ahead of print] (IF 4.582)
 101. Wolf I, Bose S, Desmond JC, Lin BT, Williamson EA, Karlan BY, Koeffler HP. **Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer.** *Breast Cancer Res Treat*. 2007 Oct; 105(2):139-55. (IF 4.671)
 102. Wolf I, Bose S, Williamson EA, Miller CW, Karlan BY, Koeffler HP. **FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer.** *Int J Cancer*. 2007 Mar 1;120(5):1013-22. (IF 4.693)
 103. Wolf I, O'Kelly J, Wakimoto N, Nguyen A, Amblard F, Karlan BY, Arbiser JL, Koeffler HP. **Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest.** *Int J Oncol*. 2007 Jun;30(6):1529-37 (IF 2.556)
 104. Wolf I, Urban D, Pfeffer R, Catane R, Aderka D. **High incidence of fistula formation during bevacizumab treatment in rectal cancer patients.** *Acta Oncol*. 2007; 46(4):550-3. (IF 2.362)
 105. Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shintani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, Herbst RS, O'Reilly MS. **Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.** *Mol Cancer Ther* 2007; 6(2): 471-483. (IF 5.137)

106. Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E, Papa MZ. **MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.** Breast Cancer Res Treat. 2007 Nov 18; [Epub ahead of print] (IF 4.671)
107. Yellin A, Sadetzki S, Simansky DA, Refaely Y, Chetrit A, Paley M. **The sequence of vessel interruption during lobectomy - does it affect the amount of blood retained in the lobe?** Eur J Cardiothorac Surg. 2007 Apr; 31(4):711-3 (IF 1.802)
108. Yinon Y, Beiner ME, Gotlieb WH, Korach Y, Perri T, Ben-Baruch G. **Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors.** Fertil Steril. 2007 Aug; 88(2):479-84 (IF 3.277)
109. Zidan J, Niessen RC, Laitman Y, Rozeveld D, Hofstra RM, Friedman E. **A novel MSH2 germline mutation in a Druze HNPCC family.** Fam Cancer. 2007 Jul 29; [Epub ahead of print]
110. Zilberman DE, Mor Y, Duvdevani M, Ramon J, Winkler HZ. **Retrograde intra-renal surgery for stone extraction.** Scand J Urol Nephrol. 2007; 41(3):204-7. (IF 1.089)
111. Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, Witz IP, Ben-Baruch A. **CXCL10 promotes invasion-related properties in human colorectal carcinoma cells.** Cancer Res. 2007 Apr 1; 67(7):3396-405. (IF 7.656)